Quest Diagnostics, Keysight Technologies And A Stock Up 42% Year To Date On CNBC's 'Final Trades'

On CNBC’s "Halftime Report Final Trades," Jason Snipe of Odyssey Capital Advisors said he likes Quest Diagnostics Incorporated DGX here. He said the company benefitted tremendously during the Covid-19 era, but its non-Covid revenues continue to grow.

Quest Diagnostics recently launched a novel prostate cancer test aimed at improving diagnosis and grading.

Stephanie Link of Hightower said she likes Keysight Technologies, Inc. KEYS. The company recently made one of the largest acquisitions to increase its software exposure.

Keysight recently announced its intention to acquire the entire share capital of ESI Group SA, which valued ESI Group's entire share capital at 913 million euros on a fully diluted basis.

Benzinga's analyst ratings data shows a consensus Buy rating on KEYS.

Joshua Brown of Ritholtz Wealth Management named Live Nation Entertainment, Inc. LYV as his final trade.

Live Nation Entertainment recently bought a majority interest in Páramo Presenta in Colombia for an undisclosed amount. The company's stock is up almost 42% YTD.

Don’t forget to check out our premarket coverage here

Price Action: Live Nation Entertainment shares gained 3.5% to settle at $97.63, while Keysight Technologies shares fell 0.3% to close at $169.89 on Tuesday. Quest Diagnostics shares gained 0.3% to close at $140.36 during the Tuesday’s session.

Check This Out: Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month

Photo: Shutterstock